prior_authorization_form_for_alpha1_antitrypsin_deficiency_medications
A Cigna prior authorization request form to collect clinical and administrative information for coverage review of alpha1-antitrypsin (AAT) augmentation therapies (Aralast NP, Glassia, Prolastin C, Zemaira) and related variants; includes required documentation checkboxes, administration site, dispensing source, diagnoses, and attestations used to process PA requests.
No material clinical/coverage changes
Policy summary and purpose
This is a Cigna prior authorization request form to collect clinical and administrative information for coverage review of alpha1-antitrypsin (AAT) augmentation therapies (Aralast NP, Glassia, Prolastin C, Zemaira) and related variants. The form includes required documentation checkboxes for baseline AAT level and genotype/phenotype, indication selection (eg, emphysema/COPD, panniculitis), disease-specific criteria (lung-function or oxygen requirement for emphysema; biopsy and severity for panniculitis), prior-therapy trial requirements, medication selection (vial sizes and product), administration site and dispensing source, facility/dispensing details, and prescriber attestations and signature used to process PA requests.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.